Literature DB >> 27296814

Non CF-bronchiectasis: Aetiologic approach, clinical, radiological, microbiological and functional profile in 277 patients.

Katerina Dimakou1, Christina Triantafillidou2, Michail Toumbis3, Kyriaki Tsikritsaki3, Katerina Malagari4, Petros Bakakos5.   

Abstract

BACKGROUND AND OBJECTIVES: Non-Cystic Fibrosis (CF) bronchiectasis is common in Greece but little attention has been paid to the investigation of its aetiology, clinical, radiological, microbiological and lung function profile.
METHODS: We prospectively evaluated patients with non-CF bronchiectasis confirmed by high resolution computed tomography (HRCT) of the chest. Aetiology, clinical data, radiology score, microbiological profile and lung function were investigated.
RESULTS: We evaluated 277 patients (170 women) with bronchiectasis (mean age: 60.5 ± 16 years), 64% of them being non-smokers. Post-infectious (25.2%) and past tuberculosis (TB) (22.3%) were the most commonly identified underlying conditions, while no cause was found in 34% of the patients. The main symptoms were cough (82%), mucopurulent sputum (80%), dyspnea (60%) and haemoptysis (37%). Mean duration of symptoms was 9.7 (SD 10.7) years. Infectious exacerbations were observed in 67.5% of the patients with a mean frequency of 2.3 (SD 1.4) per year. The most frequent lung function pattern was the obstructive (43.1%) while 38% of the patients had normal spirometry. Pseudomonas aeruginosa was the most common pathogen yielded in sputum cultures (43%) followed by Haemophilus influenzae (12.6%). Patients with P. aeruginosa had a more long-standing disease and worse lung function. Radiological severity of the disease was mainly related to impaired lung function, P. aeruginosa isolation in sputum and frequent exacerbations.
CONCLUSION: Data indicate that in Greece, "past" tuberculosis remains an important cause of bronchiectasis. P. aeruginosa was the predominant pathogen in the airways, associated with disease severity, while the most common lung function impairment was obstruction.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bronchiectasis; Epidemiology; Lung function; Microbiology; Radiology

Mesh:

Year:  2016        PMID: 27296814     DOI: 10.1016/j.rmed.2016.05.001

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  17 in total

1.  Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis.

Authors:  Adoración Navarro-Torné; Eva Agostina Montuori; Vasiliki Kossyvaki; Cristina Méndez
Journal:  Hum Vaccin Immunother       Date:  2021-06-09       Impact factor: 4.526

Review 2.  Global impact of bronchiectasis and cystic fibrosis.

Authors:  Margarida Redondo; Holly Keyt; Raja Dhar; James D Chalmers
Journal:  Breathe (Sheff)       Date:  2016-09

3.  Impact of chronic Pseudomonas aeruginosa infection on health-related quality of life in Mycobacterium avium complex lung disease.

Authors:  Hirofumi Kamata; Takanori Asakura; Shoji Suzuki; Ho Namkoong; Kazuma Yagi; Yohei Funatsu; Satoshi Okamori; Shunsuke Uno; Yoshifumi Uwamino; Hiroshi Fujiwara; Tomoyasu Nishimura; Makoto Ishii; Tomoko Betsuyaku; Naoki Hasegawa
Journal:  BMC Pulm Med       Date:  2017-12-13       Impact factor: 3.317

Review 4.  Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis.

Authors:  Ravishankar Chandrasekaran; Micheál Mac Aogáin; James D Chalmers; Stuart J Elborn; Sanjay H Chotirmall
Journal:  BMC Pulm Med       Date:  2018-05-22       Impact factor: 3.317

Review 5.  Why, when and how to investigate primary ciliary dyskinesia in adult patients with bronchiectasis.

Authors:  Martina Contarini; Amelia Shoemark; Jessica Rademacher; Simon Finch; Andrea Gramegna; Michele Gaffuri; Luca Roncoroni; Manuela Seia; Felix C Ringshausen; Tobias Welte; Francesco Blasi; Stefano Aliberti; James D Chalmers
Journal:  Multidiscip Respir Med       Date:  2018-08-09

6.  Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab.

Authors:  Giovanna E Carpagnano; Giulia Scioscia; Donato Lacedonia; Giacomo Curradi; Maria Pia Foschino Barbaro
Journal:  J Asthma Allergy       Date:  2019-03-05

7.  Characterization of the severity of dyspnea in patients with bronchiectasis: correlation with clinical, functional, and tomographic aspects.

Authors:  Maria Cecília Nieves Maiorano de Nucci; Frederico Leon Arrabal Fernandes; João Marcos Salge; Rafael Stelmach; Alberto Cukier; Rodrigo Athanazio
Journal:  J Bras Pneumol       Date:  2020-06-15       Impact factor: 2.624

8.  ECG Abnormalities in Patients with Acute Exacerbation of Bronchiectasis and Factors Associated with High Probability of Abnormality.

Authors:  Fatima Alhamed Alduihi
Journal:  Pulm Med       Date:  2021-07-05

9.  Prevalence and burden of bronchiectasis in a lung cancer screening program.

Authors:  Maria Sanchez-Carpintero Abad; Pablo Sanchez-Salcedo; Juan P de-Torres; Ana B Alcaide; Luis M Seijo; Jesus Pueyo; Gorka Bastarrika; Javier J Zulueta; Arantza Campo
Journal:  PLoS One       Date:  2020-04-13       Impact factor: 3.240

10.  Etiology, Clinical, Radiological, and Microbiological Profile of Patients with Non-cystic Fibrosis Bronchiectasis at a Tertiary Care Hospital of Pakistan.

Authors:  Nadia Sharif; Mirza Saifullah Baig; Sana Sharif; Muhammad Irfan
Journal:  Cureus       Date:  2020-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.